feed,title,long_url,short_url
Benzinga,Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock,https://benzinga.com/general/biotech/22/09/29045732/biogen-analyst-expect-20-25-upside-in-shares-after-partnered-alzheimers-antibody-treatment-candid,https://bit.ly/3fqGzRc
